10-K: Myomo Reports Fiscal Year 2024 Results, Highlights Growth and Strategic Initiatives

Myomo, Inc. reports increased product revenue and outlines strategic plans for 2025, including expanding its direct billing channel and O&P partnerships.

Summary

• Myomo, Inc. reported a net loss of $6.2 million for fiscal year 2024, compared to a net loss of $8.1 million in 2023.
• Product revenue increased by 86% to $32.6 million in 2024, driven by higher direct billing revenues and a higher average selling price.
• Direct billing revenues accounted for 78% of product revenue in 2024, while revenues from Medicare Part B patients represented 49% of total revenue.
• The company plans to increase clinical, reimbursement, and manufacturing capacity in 2025, hiring over 100 additional employees.
• Myomo is focused on expanding its O&P channel and international presence, with ongoing efforts in Germany and Australia.
• The company's cash, cash equivalents, and short-term investments totaled $25.2 million as of December 31, 2024.
• CMS published final payment determinations for the MyoPro Motion W (L8701) and the MyoPro Motion G (L8702), effective April 1, 2024, which were subsequently updated to approximately $34,300 and $67,500, respectively, effective January 1, 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While revenue growth and strategic initiatives are positive, ongoing losses, reliance on key payers, and a material weakness in internal controls temper the overall outlook.

Positives

• Significant increase in product revenue driven by direct billing and Medicare Part B reimbursements.
• Expansion of the reimbursement pipeline and backlog indicates growing demand for MyoPro devices.
• Strategic initiatives to increase clinical, reimbursement, and manufacturing capacity to support future growth.
• Successful equity offerings in 2024 provided substantial capital to fund operations and expansion plans.
• Positive cash flow from operations in the fourth quarter of 2024.
• CMS reclassification of MyoPro into the brace benefit category allowing for lump sum reimbursement.

Negatives

• History of operating losses and accumulated deficit.
• Concentration of direct billing revenues with a small number of payers, including CMS.
• Material weakness in internal controls related to information technology general controls.
• Dependence on a single third-party manufacturer for key subassemblies.
• Potential for increased competition due to the publishing of fees for HCPCS billing codes.

Risks

• Inability to obtain adequate third-party payer reimbursement, including reimbursement by Medicare.
• Adverse changes in reimbursement policies of key payers could negatively impact revenues.
• Failure to expand market acceptance or grow revenues in the orthotics and prosthetics channel.
• Defects in products or software could adversely affect operations.
• Cyber-attacks or security breaches could disrupt product development programs.
• Reliance on third parties for manufacturing and supply of key components.
• Potential for product liability claims and litigation.
• Fluctuations in quarterly and annual results due to various factors, including reimbursement timing and product mix.
• Continued inflation may materially impact financial operations or results of operations.
• Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations.

Future Outlook

Myomo plans to invest in increasing demand and adding capacity to support its direct billing channel, while also focusing on growing revenues in the O&P channel. The company expects negative cash flows for at least the first three quarters of 2025.

Management Comments

• The company plans to increase clinical, reimbursement, and manufacturing capacity in 2025, hiring over 100 additional employees.
• Myomo is focused on expanding its O&P channel and international presence, with ongoing efforts in Germany and Australia.

Industry Context

The report highlights Myomo's position in the wearable medical robotics industry, specifically focusing on myoelectric orthotics. The company faces competition from other medical device manufacturers and must navigate evolving healthcare regulations and reimbursement policies.

Comparison to Industry Standards

• The document mentions competition from companies such as Neurolutions in the United States and Vincent Systems and HKK Bionics in Germany.
• The company's success depends on its ability to compete effectively against current technology and respond to technological advances.
• The report notes that the development of new or improved products by other companies may render Myomo's products obsolete or less competitive.
• The company's ability to secure adequate quantities of such products may be limited.
• The company's ability to secure financing and the cost of raising such capital are dependent on numerous factors, including general economic and capital markets conditions, credit availability from lenders, investor confidence and the existence of regulatory and tax incentives that are conducive to raising capital.

Corporate Governance

Legal Proceedings

• The Company may be involved in legal proceedings, claims and assessments arising from the ordinary course of business.

Stakeholder Impact

• Shareholders: Dilution from equity offerings, potential for increased stock value with revenue growth.
• Employees: Increased hiring and potential for career advancement.
• Customers: Improved access to MyoPro devices through expanded channels.
• Suppliers: Potential for increased orders and business opportunities.

Next Steps

• Increase advertising spending and clinical capacity to grow revenues in the direct billing channel.
• Expand the O&P channel and international operations.
• Continue to improve internal control over financial reporting.
• Monitor and adapt to changes in healthcare regulations and reimbursement policies.

Key Dates